. Author manuscript; available in PMC: 2024 Feb 1.

Published in final edited form as: Lancet Rheumatol. 2023 Jan 24;5(2):e67–e76. doi: 10.1016/s2665-9913(23)00003-6

Table 2.

Changes in Creatine Kinase Levels from Baseline to Week 8 (ITT population)

	Zilucoplan 0·3mg/kg N=12	Placebo N=15
	n=10	n=14
Mean percent change from baseline (SD) ^*	−9·9 (26·1)	−20·7 (31·2)
Median (Min, Max)	−15·1 (−37·3, 44·5)	−16.3 (−80·0, 18·2)
Stratified^†
p-value^‡		0·46
Wilcoxon-Mann-Whitney odds		0·55
95% CI		0·19, 1·57

CI=confidence interval, Max=maximum, Min=minimum, SD=standard deviation.

Week 8 CK values were not available for 3 participants (two in the zilucoplan arm and one in the placebo arm)

^†

Primary efficacy analysis.

^‡

Based on a 2-sided Van Elteren test.